Transition between RRMS and SPMS

 


 

The transition period between RRMS and SPMS is loosely defined [1]. A study largely looking into this phase of MS is the European Betaferon trial in secondary progressive MS [2]. About 70% of patients in this study (n=718) had superimposed relapses on their progressive phase at study entrance [2]. The study achieved positive results in favor of Betaferon treatment across the spectrum of clinical and MRI outcomes [2] and led to the approval of Betaferon as a treatment for secondary progressive MS with superimposed relapses [2,3].

 

Patients on Betaferon compared to placebo had:

  • a 1.6 times lower probability of disability progression [2]
  • a 1.5 times lower probability of becoming wheelchair bound [2]
  • about 33% fewer relapses [4]
  • about 65-78% fewer newly active lesions (months 1-6 and 19-24) [2].

 

References

  • Freedman MS et al. J Neurol 2020; 267(1): 64-75. Return to content
  • European Study Group. Lancet 1998; 352(9139): 1491-7. Return to content
  • BETAFERON® European Summary of Product Characteristics, October 2020. Available at: https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information_en.pdf. Return to content
  • Kappos L et al. Neurology 2004; 63(10): 1779-87. Return to content
Alt tag